M
7.83
-0.01 (-0.13%)
| Previous Close | 7.84 |
| Open | 7.88 |
| Volume | 309,351 |
| Avg. Volume (3M) | 414,304 |
| Market Cap | 629,903,744 |
| Price / Earnings (Forward) | 1.61 |
| Price / Sales | 17.20 |
| Price / Book | 228.30 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2025 |
| Operating Margin (TTM) | -2,159.71% |
| Diluted EPS (TTM) | -2.31 |
| Quarterly Revenue Growth (YOY) | 176.30% |
| Total Debt/Equity (MRQ) | 244.35% |
| Current Ratio (MRQ) | 1.52 |
| Operating Cash Flow (TTM) | -104.58 M |
| Levered Free Cash Flow (TTM) | -53.25 M |
| Return on Assets (TTM) | -37.28% |
| Return on Equity (TTM) | -216.14% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | MeiraGTx Holdings plc | Bearish | Bullish |
AIStockmoo Score
1.4
| Analyst Consensus | 3.0 |
| Insider Activity | -1.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | 4.0 |
| Average | 1.40 |
|
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 24.27% |
| % Held by Institutions | 60.04% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 35.00 (Chardan Capital, 347.00%) | Buy |
| Median | 32.00 (308.69%) | |
| Low | 29.00 (Raymond James, 270.37%) | Buy |
| Average | 32.00 (308.69%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 8.72 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Raymond James | 21 Oct 2025 | 29.00 (270.37%) | Buy | 9.26 |
| Chardan Capital | 15 Aug 2025 | 35.00 (347.00%) | Buy | 8.17 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| GIROUX RICHARD | - | 9.26 | -24,000 | -222,240 |
| Aggregate Net Quantity | -24,000 | |||
| Aggregate Net Value ($) | -222,240 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 9.26 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| GIROUX RICHARD | Officer | 21 Oct 2025 | Automatic sell (-) | 24,000 | 9.26 | 222,240 |
| Date | Type | Details |
|---|---|---|
| 07 Oct 2025 | Announcement | MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress |
| 14 Aug 2025 | Announcement | MeiraGTx Reports Second Quarter 2025 Financial and Operational Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |